An Evidence-Based Examination of Administration of Infliximab 05-115-18-023 RN Member
10 Questions
An Evidence-Based Examination of Administration of Infliximab 05-115-18-023 RN Member

Remicade (Infliximab [IFX]), the first tumor necrosis factor-alpha (TNF-α) antagonist approved by the U.S. Food and Drug Administration (FDA), has become one of the most prescribed biologic agents in the country and a mainstay of the home infusion industry.  Safe administration requires a comprehensive knowledge  the mechanism of action and prescribing information, as well as the ability to manage and prevent infusion reactions.

NHIA Member #
Email








Please wait...

Previous session detected

Resume Quiz